Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Ovarian Function Suppression And ExemesTane With or Without PalbocIclib in PreMenopausal Women With ER Positive / HER-2 Negative MetAstatic Breast Cancer

NCT02917005 is registered in ClinicalTrials.gov with Hamdy A. Azim as lead sponsor.

NCT NCT02917005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02917005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Ovarian Function Suppression And ExemesTane With or Without PalbocIclib in PreMenopausal Women With ER Positive / HER-2 Negative MetAstatic Breast Cancer
Lead sponsor
Hamdy A. Azim
Phase
Phase 2
Overall status
Unknown status
Start date
May 7, 2019
Completion date
December 31, 2023
Enrollment
160 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer